<DOC>
	<DOCNO>NCT01394315</DOCNO>
	<brief_summary>The aim study determine DOT detect response early breast cancer patient undergo neoadjuvant chemotherapy .</brief_summary>
	<brief_title>Diffuse Optical Tomography ( DOT ) Monitoring Response Neoadjuvant ( Preoperative ) Chemotherapy Breast Cancer</brief_title>
	<detailed_description>The pilot study enrol ten patient one year . Patients receive neoadjuvant chemotherapy breast cancer undergo baseline clinical examination , mammography , ultrasound , MRI DOT commencement treatment . DOT repeat 1,3,6 week chemotherapy , end chemotherapy regimen . Ultrasound repeat every 6 week end treatment . Mammography MRI repeat end treatment surgery . A breast pathologist evaluate subtype breast cancer pathologic response operative specimen end treatment . Patient satisfaction questionnaire administer evaluate preference DOT , ultrasound , mammography MRI scan begin end study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Patients receive neoadjuvant chemotherapy breast cancer . Patients locally advance breast tumour large operable tumour require neoadjuvant treatment downstaging . Histological confirmation invasive breast carcinoma . Patients metastatic disease may eligible oligometastatic disease breast surgery neoadjuvant chemotherapy plan . Signed informed consent Age equal 21 year Life expectancy great 12 week . ECOG performance status 02 Fungating ulcerated tumour Inability provide informed consent Anticipated inability followup patient response chemotherapy Any contraindication undergoing ultrasound , MRI , MMG DOT</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>diffuse optical tomography</keyword>
	<keyword>response</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>breast cancer</keyword>
</DOC>